title: Should your algorithm include plasma rich in growth factors in the light of its clinical efficacy and safety?: By Vaquerizo V. et al.
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. Electronic address: olivier.bruyere@ulg.ac.be.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bruyère
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
authors.affiliation: MRC Life course Epidemiology Unit, University of Southampton, Southampton, UK; NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
authors.forename: Cyrus
authors.initials: C
authors.lastname: Cooper
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008297:Male; D020370:Osteoarthritis, Knee / Q000628:therapy*; D010949:Plasma / Q000737:chemistry*
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D006820:Hyaluronic Acid